Citations 2
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
Palta, Manisha , Rushing, Christel , Selim, M. Angélica , Linney, Kristen N., Czito, Brian G. , Yoo, David S., Hanks, Brent A. , Beasley, Georgia M. , Mosca, Paul J. , Dumbauld, Chelsae, Steadman, Katelyn N., Yi, John S. , Weinhold, Kent J. , Tyler, Douglas S. , Lee, Walter T. , Watters, Chelsae R , Rushing, Christel N , Hanks, Brent A , Beasley, Georgia M , Mosca, Paul J , Lee, Walter T , Brizel, David M , Dumbauld, Chelsae , Salama, April K.S. , Brizel, David M.
Clinical Cancer Research | November 10, 2020 | Volume: 27 | Issue: 5 | Pages: 1287-1295
Abstract Purpose: In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma. Patients and Methods: Twenty-four patients in two cohorts were enrolled and received ipilimumab at 3 mg/kg every 3 weeks for four doses in conjunction with radiation; median dose was 4,000 cGy (interquartile range, 3,550–4,800 cGy). Patients in cohort 1 were treated adjuvantly; patients in cohort 2 were treated either neoadjuvantly or as definitive therapy. Results: Adverse event profiles were consistent with those previously reported with checkpoint inhibition and radiation. For the neoadjuvant/definitive cohort, the objective response rate was 64% (80% confidence interval, 40%–83%), with 4 of 10 evaluable patients achieving a radiographic complete response. An additional 3 patients in this cohort had a partial response and went on to surgical resection. With 2 years of follow-up, the 6-, 12-, and 24-month relapse-free survival for the adjuvant cohort was 85%, 69%, and 62%, respectively. At 2 years, all patients in the neoadjuvant/definitive cohort and 10/13 patients in the adjuvant cohort were still alive. Correlative studies suggested that response in some patients were associated with specific CD4+ T-cell subsets. Conclusions: Overall, concurrent administration of ipilimumab and radiation was feasible, and resulted in a high response rate, converting some patients with unresectable disease into surgical candidates. Additional studies to investigate the combination of radiation and checkpoint inhibitor therapy are warranted.
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology
Darragh, Teresa M. , Colgan, Terence J. , Cox, J. Thomas, Heller, Debra S. , Henry, Michael , Luff, Ronald D., McCalmont, Timothy H. , Nayar, Ritu , Stoler, Mark H. , Wilkinson, Edward J., Zaino, Richard J., Wilbur, David C. , Luff, Ronald D., Wilkinson, Edward J., Wilkinson, Edward J., O’Connor, Dennis M., Reynolds, R. Kevin, Selim, M. Angélica , Scurry, James , Chelmow, David , Howell, Lydia, Ronnett, Brigitte M., Waxman, Alan G., Haefner, Hope K. , Leslie, Kieron , Lytwyn, Alice, Winkler, Barbara , Colgan, Terence J., Downs, Levi S., Laucirica, Rodolfo, Allbritton, Jill, Ioffe, Olga B. , Joste, Nancy E., Berry, J. Michael, Lin, Oscar , Welton, Mark L., Otis, Christopher N. , Stoler, Mark H. , Bentz, Joel S., Quade, Bradley J. , Schwartz, Mary R. , Luff, Ronald D., Castle, Philip E. , García, Francisco , Moriarty, Ann , Niedt, Greg , Carter, Alicia , Neal, Margaret B., Reddy, Vijaya , Robboy, Stanley J. , Spires, Susan E., Luff, Ronald D., Palefsky, Joel Michael , Wilkinson, Edward J., Wilkinson, Edward J., Shea, Christopher Michael , Staats, Paul N. , Roberts, Jennifer Margaret , Colgan, Terence J., Kong, Christina S. , Luff, Ronald D., Duggan, Máire A. , Goodman, Marc T. , Saraiya, Mona , Silverberg, Steven M.
Archives of Pathology & Laboratory Medicine | June 28, 2012 | Volume: 136 | Issue: 10 | Pages: 1266-1297
Abstract The terminology for human papillomavirus (HPV)–associated squamous lesions of the lower anogenital tract has a long history marked by disparate diagnostic terms derived from multiple specialties. It often does not reflect current knowledge of HPV biology and pathogenesis. A consensus process was convened to recommend terminology unified across lower anogenital sites. The goal was to create a histopathologic nomenclature system that reflects current knowledge of HPV biology, optimally uses available biomarkers, and facilitates clear communication across different medical specialties. The Lower Anogenital Squamous Terminology (LAST) Project was cosponsored by the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology and included 5 working groups; 3 work groups performed comprehensive literature reviews and developed draft recommendations. Another work group provided the historical background and the fifth will continue to foster implementation of the LAST recommendations. After an open comment period, the draft recommendations were presented at a consensus conference attended by LAST work group members, advisors, and representatives from 35 stakeholder organizations including professional societies and government agencies. Recommendations were finalized and voted on at the consensus meeting. The final, approved recommendations standardize biologically relevant histopathologic terminology for HPV-associated squamous intraepithelial lesions and superficially invasive squamous carcinomas across all lower anogenital tract sites and detail the appropriate use of specific biomarkers to clarify histologic interpretations and enhance diagnostic accuracy. A plan for disseminating and monitoring recommendation implementation in the practicing community was also developed. The implemented recommendations will facilitate communication between pathologists and their clinical colleagues and improve accuracy of histologic diagnosis with the ultimate goal of providing optimal patient care.